COVID-19 convalescent plasma is an investigational treatment in which plasma collected from people who have recovered from COVID-19 is transfused into patients with active infection. The plasma contains antibodies generated during recovery, including neutralizing antibodies that can bind and inactivate SARS-CoV-2, w…
COVID-19 convalescent plasma is an investigational treatment in which plasma collected from people who have recovered from COVID-19 is transfused into patients with active infection. The plasma contains antibodies generated during recovery, including neutralizing antibodies that can bind and inactivate SARS-CoV-2, with the aim of providing passive immunity while the recipient mounts their own response. Convalescent plasma has been explored for various infectious diseases, and during the COVID-19 pandemic it was studied as a potential early intervention, with factors such as antibody titer, timing, and donor selection influencing its use. Research published by this journal addresses the basis of this approach. A study on the presentation of neutralizing antibodies in single- or pooled-convalescent immune plasma from donors examines how plasma might be prepared and characterized to counter the spread of SARS-CoV-2, reflecting interest in the antibody content that underpins convalescent plasma therapy. This page gathers peer-reviewed, open-access research relevant to COVID-19 convalescent plasma, supporting readers seeking primary literature on antibody-based and plasma-derived approaches to coronavirus infection.
1 peer-reviewed article, ranked by relevance. Each links to its DOI.
The 1 article above has been cited 4 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Oct 2025.
A sample of recent works citing this journal's research on Covid-19 Convalescent Plasma, linking to each citing work.